There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.
Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.
Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat ...
Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...
Trevi Therapeutics Investor and Analyst Day May 7, 2026, Midtown New York, New York 10:00 a.m. to 12:00 p.m. ET Representatives: Trevi senior management will be joined by key opinion leaders in ...
Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior ...
Plus, when to see a doctor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results